AR115913A1 - Formas de dosificación oral biodisponibles, uso, métodos - Google Patents

Formas de dosificación oral biodisponibles, uso, métodos

Info

Publication number
AR115913A1
AR115913A1 ARP190102223A ARP190102223A AR115913A1 AR 115913 A1 AR115913 A1 AR 115913A1 AR P190102223 A ARP190102223 A AR P190102223A AR P190102223 A ARP190102223 A AR P190102223A AR 115913 A1 AR115913 A1 AR 115913A1
Authority
AR
Argentina
Prior art keywords
oral dosage
methods
dosage forms
polymer
available oral
Prior art date
Application number
ARP190102223A
Other languages
English (en)
Inventor
Mandar V Dali
Akm Nasir Uddin
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of AR115913A1 publication Critical patent/AR115913A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un producto intermedio secado por pulverización que comprende una forma amorfa de un Compuesto que tiene la fórmula (1), y un polímero, en el que el polímero es un polímero hidrófilo. Reivindicación 2: El producto intermedio secado por pulverización de la reivindicación 1, en el que el polímero es polivinilpirrolidona o hidroxipropilmetilcelulosa. Reivindicación 8: Una composición farmacéutica que comprende el producto intermedio secado por pulverización de la reivindicación 1 es una mezcla íntima con uno o más excipientes farmacéuticamente aceptables para proporcionar una forma farmacéutica oral seleccionada entre un comprimido o una cápsula.
ARP190102223A 2018-08-03 2019-08-05 Formas de dosificación oral biodisponibles, uso, métodos AR115913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03

Publications (1)

Publication Number Publication Date
AR115913A1 true AR115913A1 (es) 2021-03-10

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102223A AR115913A1 (es) 2018-08-03 2019-08-05 Formas de dosificación oral biodisponibles, uso, métodos

Country Status (23)

Country Link
US (1) US20210205225A1 (es)
EP (1) EP3829544A1 (es)
JP (1) JP2021532193A (es)
KR (1) KR20210041589A (es)
CN (1) CN112752570A (es)
AR (1) AR115913A1 (es)
AU (1) AU2019316036A1 (es)
BR (1) BR112021001859A2 (es)
CA (1) CA3107737A1 (es)
CL (1) CL2021000271A1 (es)
CO (1) CO2021001979A2 (es)
CR (1) CR20210093A (es)
EA (1) EA202190429A1 (es)
EC (1) ECSP21011795A (es)
IL (1) IL280471A (es)
MX (1) MX2021001364A (es)
NI (1) NI202100006A (es)
PE (1) PE20211410A1 (es)
PH (1) PH12021550237A1 (es)
SG (1) SG11202100984VA (es)
TN (1) TN2021000021A1 (es)
TW (1) TW202019414A (es)
WO (1) WO2020028778A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2763485C (en) 2009-05-27 2018-05-15 Neil Almstead Methods for treating cancer and non-neoplastic conditions
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1729741A2 (en) 2004-03-03 2006-12-13 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
DK1737461T3 (da) 2004-03-15 2013-03-18 Ptc Therapeutics Inc Carbolin-derivater til inhibering af angiogenese
WO2008127714A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
CA2763485C (en) 2009-05-27 2018-05-15 Neil Almstead Methods for treating cancer and non-neoplastic conditions
WO2017091373A1 (en) * 2015-11-25 2017-06-01 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms

Also Published As

Publication number Publication date
CR20210093A (es) 2021-05-28
WO2020028778A1 (en) 2020-02-06
JP2021532193A (ja) 2021-11-25
IL280471A (en) 2021-03-25
CA3107737A1 (en) 2020-02-06
PH12021550237A1 (en) 2021-10-11
MX2021001364A (es) 2021-04-13
BR112021001859A2 (pt) 2021-04-27
ECSP21011795A (es) 2021-03-31
AU2019316036A1 (en) 2021-03-04
KR20210041589A (ko) 2021-04-15
US20210205225A1 (en) 2021-07-08
EP3829544A1 (en) 2021-06-09
EA202190429A1 (ru) 2021-06-15
SG11202100984VA (en) 2021-02-25
CO2021001979A2 (es) 2021-03-08
TN2021000021A1 (en) 2022-10-03
CN112752570A (zh) 2021-05-04
CL2021000271A1 (es) 2021-08-20
TW202019414A (zh) 2020-06-01
NI202100006A (es) 2021-05-21
PE20211410A1 (es) 2021-08-02

Similar Documents

Publication Publication Date Title
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
CO2019008364A2 (es) Composiciones farmacéuticas que comprenden meloxicam
CO2019002556A2 (es) Composición farmacéutica
CO2021000789A2 (es) Composiciones farmacéuticas que comprenden meloxicam
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
BR112018067586A2 (pt) composição administrável oralmente
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
DOP2011000093A (es) Inhibidores de la integrasa del vih
CO6531485A2 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
WO2019194773A3 (en) The combination comprising linagliptin and metformin
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
CL2020001358A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
ECSP21072036A (es) Composición farmacéutica que contiene acetaminofeno e ibuprofeno
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
ECSP15033649A (es) Un medicamento combinado que comprende fenilefrina y paracetamol
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
AR067351A1 (es) Combinacion de picotamida con nafronil
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
ECSP17008187A (es) Formas de dosificación farmacéutica
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
NI201900084A (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas